Galaxy Therapeutics received CE mark approval under the European Medical Device Regulation for its SEAL embolization system, designed for treatment of ruptured and unruptured wide-neck intracranial aneurysms. Galaxy said the device is intended to simplify aneurysm procedures across complex anatomies and provide an alternative for wide-neck bifurcation aneurysms. The CE mark supports European commercial rollout and strengthens Galaxy’s position in endovascular neuromodality where device differentiation and clinical evidence often determine adoption. For hospitals, the decision expands options for wide-neck aneurysm management with an additional regulated device pathway in Europe.